HHS on Monday (June 22) paid another $102 million for convalescent plasma out of $500 million that’s been set aside for the blood product, and FDA Commissioner Stephen Hahn said the agency is considering authorizing emergency use of the product to treat COVID-19 patients. The Mayo Clinic this week released promising preliminary results from a study of 20,000 patients treated with the plasma. Convalescent plasma is made from blood donated by patients who recently recovered from COVID-19. The plasma is...